Similarly, a recently developed framework for the prioritization of drug targets based on functional genomic features, immune-related annotations and network connectivity in RA showed that top prioritized genes were linked to a few approved drugs such as abatacept, tocilizumab, and TNF-inhibitors [116,117,118]. Here, TNF is linked to rheumatoid arthritis.